CENTRAL POINT, OR; Global pharmaceutical company Boehringer Ingelheim recently finalized their partnership with Dogs for Better Lives (DBL) for 2025. This national partnership includes marketing support, presenting sponsorship of Bone AppeTREAT, and providing vaccine and pharmaceutical products to DBL puppies, Service Dogs in training and staff pets.
Recent social post on LinkedIn, promoting Boehringer Ingelheim’s corporate partnership with DBL.
“I’m pleased to support Dogs for Better Lives and their Service Dogs in training,” stated Dr. Julie Ryan-Johnson, Senior Associate Director, Shelter and Nonprofit Engagement. “As a corporate partner and more recently as a national board member, I truly appreciate that our corporate contributions are helping to make a difference in the lives of these amazing dogs in training, while preparing them to go out into the world to better the lives of people with disabilities.”
In 2025, Boehringer Ingelheim will be entering their third year of this partnership with DBL, having provided general support as well as in-kind vaccine product in the past.
“This partnership with Boehringer Ingelheim is monumental in providing significant financial and in-kind support to DBL at a time when the organization is going through major national growth and expansion,” stated CEO Bryan Williams. “We are so appreciative of Dr. Ryan-Johnson and Boehringer Ingelheim’s contributions.”
In May of this year, Boehringer Ingelheim was a Leader of the Pack sponsor of DBL’s signature event Bone AppeTREAT, which engaged selected contestants across the country, in creating human grade dog treats, while vying to become Top Dog. For the 2025 event, Boehringer Ingelheim has committed to Presenting Sponsor of the 3rd annual event.
“What Boehringer Ingelheim represents and offers as a national corporate partner to DBL is impressive, stated board chair, Tom Dobry. “It certainly sets the bar high, as to what the DBL Team envisions and is striving for with future partnerships.”
Mock-up of future DBL vehicle wrap, promoting Boehringer Ingelheim’s NexGard PLUS, vaccines used on all dogs in training.
In 2025, Boehringer Ingelheim and DBL, will be launching a new collaborative branding initiative, focusing on the nonprofit’s wrap on new vehicles going forward. Further DBL will be promoting the global pharmaceutical company in monthly social posts, helping to educate the public on the importance of properly vaccinated dogs. Boehringer Ingelheim has even taken it one step further, in providing Healthy Habit Kits including NexGard PLUS to DBL staff’s pets.
Boehringer Ingelheim is a global pharmaceutical company that develops and manufactures treatments for humans and animals, working to improve the lives of people and animals through research, development, and innovation. Founded in 1885 by Albert Boehringer in Ingelheim, Germany the family-owned company has more than 53,000 employees globally and serves more than 130 markets worldwide.
For more information on Corporate Partnership opportunities, please visit https://dogsforbetterlives.org/corporate-partners_new/
For more information on Bone AppeTREAT, please visit www.dogsforbetterlives.org/boneappetreat. With sponsorship inquiries for Bone AppeTREAT, please contact Harvey Potts, harvey@dogsforbetterlives.org.
